Notice of Patent Registration (Russia) for Regen-Inducing Drug Redasemotide (HMGB1 Fragment Peptide) Indicated for Fatty Liver and Non-Alcoholic Steatohepatitis

News Overview

This release notifies that a use patent for fatty liver and nonalcoholic steatohepatitis (NASH) treatment using regenerative medicine®-developed redasemtide may be registered in Russia. Applicants are StemRim, Osaka University, and Niigata University (National University Corporation Osaka University, National University Corporation Niigata University). Invention title: Drug for treatment of fatty liver and nonalcoholic steatohepatitis. Filing region: Russia. Application number: 2024111536. Publication registration number: To be determined. At present, there is no anticipated impact on the full-year results for the fiscal year ending July 2026.

Impact on Business & Strategy

The patent registration aims to broaden the scope of application for redasemtide, enhancing the potential for global expansion including the Russian market. The program is currently in development, driven by the urgent need for new treatments in the fatty liver/NASH space. In the long term, market opportunities are expected from expanded drug indications, but the direct financial impact at this time is unknown.